Cerebras–G42

G42's commitments to make $1.43B in purchases from Cerebras and buy $335M in its shares ended in 2025. Cerebras has since granted G42 shares at almost no cost.

A deal between Cerebras, G42

Why it matters

The collapse of G42's commitment to buy $335M of Cerebras shares at a fixed, discounted price produced the $363M accounting gain behind Cerebras's apparent IPO profitability. Cerebras still depended heavily on a customer in the same Emirati orbit, a concentration disclosed only in Cerebras's filings.

Tap a figure for the line in its source.

G42 gives Cerebras

  • of committed purchases from Cerebras (May 2024); terminated in 2025
  • for Cerebras shares at a fixed, discounted price, committed May 2024 subject to US approval; never paid — the purchase lapsed in 2025
  • for about 1% of Cerebras, Nov 2021

Cerebras gives G42

  • at $0.01 each, granted Dec 2025 for being a customer; 1,655,975 more in Apr 2026

Sep 30, 2024 revealed in Cerebras's IPO filingupdated Nov 19, 2026commercial commitments terminated 2025 disclosed by the parties

What happened

Before the OpenAI deal, Abu Dhabi conglomerate G42 was both an investor in Cerebras and its biggest customer. It bought a ~1% stake in 2021. It accounted for 83–85% of Cerebras's revenue in 2023–24. In May 2024, it committed, subject to US approval, to buy $335 million more of Cerebras's shares at a fixed, discounted price. Large orders would unlock a separate option to buy more. During the US national-security review, the shares were changed to non-voting. In March 2025 the reviewers let the parties withdraw their filing. The share purchase was not completed by its April 15, 2025 deadline. In 2025, the option and the entire $1.43 billion purchase agreement were terminated. An accounting quirk turned the lapsed purchase into a one-time $363 million paper gain. That made Cerebras appear profitable in 2025, the year before its IPO. Cerebras still depended heavily on a single customer in the same Abu Dhabi orbit. MBZUAI, an Abu Dhabi state university, grew to account for 62% of revenue. Only Cerebras's own filings disclose that share. Cerebras also gave G42 two , or rights to buy shares for a penny each, for being a customer. It issued the warrants in December 2025 and April 2026. Both have since been exercised in full.

Sources 10 documents — 10 SEC filings

Research trail Found 861 documents and read 714 of them while checking this deal and related ones.

  1. SEC filingsec.gov
    States 4 figures: penny warrant dec 2025 · penny warrant apr 2026 · 9% concentration trajectory · 45% mbzuai Q3 2026
  2. SEC filingsec.gov
    States 2 figures: $40M 2021 stake · $350M mbzuai po
  3. SEC filingsec.gov
    States 2 figures: $335M equity option terms · 62% mbzuai rotation
  4. Cerebras · SEC filingsec.gov
    States $1,429,898,688 commercial commitment
  5. Cerebras · SEC filingsec.gov
    States $300,000,000 prepayment
  6. SEC filingsec.gov
    States mbzuai po dec 2025
  7. SEC filingsec.gov
    States $363.3M termination and gain
  8. SEC filingsec.gov
    Cited by the record; no single figure is quoted from it.
  9. SEC filingsec.gov
    Cited by the record; no single figure is quoted from it.
  10. SEC filingsec.gov
    Cited by the record; no single figure is quoted from it.

The record's own summary of its sourcing: Cerebras S-1 (filed Sep 30 2024, and in 2026) + S-1/A + 424B4 + Q1 and Q3 2026 10-Qs + PO/letter exhibits (SEC) · as of Nov 2026

The evidence 12 sourced figures · 2 disputes

The record's headline Cerebras–G42: investor + 83%-customer with a $335M share-purchase commitment and a separate purchase-scaled equity option — both ended, rotated to MBZUAI

Size
$1.43B commitment (terminated) + $335M share purchase (lapsed) + penny warrants (exercised)
When
Nov 2021 → Apr 2026
Status
commercial commitments terminated 2025; concentration rotated to MBZUAI; two $0.01 warrants, both exercised in full (Jan + Apr 2026)
Structure
customer-as-investor: purchase commitments paired with a committed share purchase at the round's discounted fixed price, a separate purchase-scaled equity option (17.5% below fair value) and penny-strike customer warrants — the OpenAI structure's G42-shaped precursor
Programme
Cerebras–G42
Parties
Cerebras supplier: warrant issuer + one-time option grantor · G42 customer + investor since 2021 (non-voting after CFIUS review)
Capital
the seller's own money or backing comes back as its sales
Record
disclosed / primary source · as of Nov 2026

Flows 3 as the record states them

  • G42 → Cerebrasequity~$40M for ~1% (Series F @ $27.74, 11/2021); the later $335M Series F-2 purchase was never consummated
  • G42 → Cerebrascompute-purchases$1.43B May-2024 aggregate commitment (incl. $300M prepaid sum + $178.7M PO; MBZUAI's $350M PO fulfilled a further portion) — terminated in its entirety 2025
  • Cerebras → G42equitytwo Class N warrants at $0.01: 1,857,516 (12/2025) + 1,655,975 (4/2026) — customer consideration, granted around the OpenAI MRA's signing and after it

Resolved figures 12 each with the verbatim line from its document

  • 2021-stake$40M
    ~1% ownership via ~1.4M Series F preferred at $27.74/sh, November 2021, ~$40M gross proceeds (implying ~$4B valuation) — the investor half of the investor-customer double role
    “acquired an approximate 1% ownership interest in our company as of such date by purchasing approximately 1.4 million shares of our Series F redeemable convertible preferred stock at $27.74 per share, resulting in gross proceeds to us of approximately $40.0 million”
    Cerebras 2024 S-1 · sec.gov
  • commercial-commitment$1,429,898,688
    US$1,429,898,688.00 aggregate products-and-services commitment (the 'G42 May 2024 Agreement') — exact contract figure in the exhibit; '$1.43B' everywhere else is the same quantity rounded, not corroboration. The $300M prepayment and the POs sat INSIDE this aggregate, not on top of it
    “purchase HPC Clusters [***] (the “[***] Condor”) at a price [***] for an aggregate amount equal to US$1,429,898,688.00”
    Series F extension letter agreement, exhibit 10.16 to 2024 S-1 · sec.gov
  • prepayment$300,000,000
    $300,000,000 'Prepaid Sum' advanced by G42 under the April 24, 2024 Letter of Award — tier-1 in the PO exhibits (the figure is not 'tier-3 only'); Cerebras held $263M restricted cash from G42 prepayments at 6/30/24
    “G42 advanced to the Supplier a sum of US$300,000,000 (the “Prepaid Sum”)”
    Purchase Order 2024-0003 exhibit to 2024 S-1 · sec.gov
  • mbzuai-po$350M
    US$350M MBZUAI purchase order (9/2024) — fulfilled a portion of the G42 May 2024 Agreement per the filings, i.e. the successor customer was paying down the predecessor's commitment; G42's own PO 2024-0003 was $178,737,336
    “agreed to purchase $350.0 million of the $1.43 billion committed pursuant to the G42 May 2024 Agreement”
    Cerebras 2024 S-1 (PO itself is exhibit 10.17 to that filing, 'Goods US$ 350 million') · sec.gov
  • mbzuai-po-dec-2025
    a second MBZUAI purchase order, 'Purchase Order 11-2025', dated Dec 30 2025 and signed for MBZUAI by its president, Eric Xing; its fee is redacted ('[***] (“Goods Fee”)'), so it adds no figure here
    “This Purchase Order is dated December 30, 2025 (the Commencement Date).”
    Cerebras April 2026 S-1, exhibit 10.17 (MBZUAI Purchase Order 11-2025) · sec.gov
  • equity-option-terms$335M
    the 'G42 Primary Purchase' — a commitment, not an option: 22,851,296 Series F-2 shares at $14.66/sh = $335M, subject to regulatory approval (CFIUS) and customary closing conditions, agreed May 2024 and committed by April 15, 2025, made non-voting during the CFIUS review. $14.66 was the round's own price (other investors paid it for the rest of Series F-1, $85.0M), roughly half the 2021 Series F's $27.74, and Cerebras booked the commitment as a forward contract at a 'discounted fixed price'. The purchase-scaled equity was the separate 'G42 Option': 17.5% below fair value, contingent on G42 buying $500.0M–$5.0B more, sized at 10% of the relevant orders' value (2024 S-1). CFIUS let the parties withdraw their notice March 27, 2025, after they agreed in principle to restructure. Not consummated by the deadline, for no reason the filings give: G42 removed as party Q3 2025, G42 Option terminated
    “22,851,296 shares were allocated to be purchased by an entity affiliated with Group 42 Holding Ltd (together with its affiliates, “G42”) for an aggregate purchase price of $335 million, subject to regulatory approval (the “G42 Primary Purchase”)”
    Cerebras 424B4 · sec.gov
  • termination-and-gain$363.3M
    the Series F-1/F-2 Agreement was restated Q3 2025 to remove G42 (terminating the G42 Option) and 'The G42 May 2024 Agreement was also terminated in its entirety' — but the gain came from the lapsed share purchase: 'As the G42 Primary Purchase was not consummated by April 15, 2025, the forward contract was extinguished', and extinguishing that forward contract liability produced a one-time non-cash $363.3M gain, the bridge from a $(145.9)M operating loss to $237.8M GAAP net income in FY2025, the last full year before the May 2026 IPO
    “includes a one-time $363.3 million gain due to the extinguishment of the Forward Contract Liability”
    Cerebras S-1/A #2 (May 2026) · sec.gov
  • penny-warrant-dec-2025up to 1,857,516
    warrant for up to 1,857,516 Class N shares at $0.01, issued to G42 December 2025 — the same month the OpenAI MRA was signed — and exercised in full January 2026. Carry the two grants separately: the aggregate '3.5M' presentation hides that the second post-dates the MRA
    “In December 2025, the Company issued a warrant to G42 (as defined above) to purchase an aggregate of up to 1,857,516 shares of Class N common stock”
    Cerebras 10-Q Q3 2026 · sec.gov
  • penny-warrant-apr-2026up to 1,655,975
    second warrant for up to 1,655,975 Class N shares at $0.01, issued April 2026 and exercised in full the same month; grant-date fair value $90.23/sh → $149.4M customer warrant asset recognized Q2'26, ALL of it a reduction of revenue — the accounting shape of paying a customer in equity
    “In April 2026, the Company issued a warrant to G42 to purchase an aggregate of up to 1,655,975 shares of Class N common stock”
    Cerebras 10-Q Q3 2026 · sec.gov
  • concentration-trajectory9%
    G42 share of total revenue: 83% FY23 → 85% FY24 (87% in H1'24, and 97% of hardware revenue that half — same disclosure, different denominators) → 24% FY25 → 11% Q1'26 → 9% of the nine months to 9/30/26 (7% in Q3, against 14% a year earlier and 30% for the first nine months of 2025). The period must travel with each number or the 83/85/86/87 spread reads as a phantom conflict
    “accounted for 7% and 14% for the three months ended September 30, 2026 and 2025, respectively, and 9% and 30% for the nine months ended September 30, 2026 and 2025, respectively”
    Cerebras 10-Q Q3 2026 (FY25's 24% and FY24's 85%: April 2026 S-1) · sec.gov
  • mbzuai-rotation62%
    MBZUAI: 62% of FY25 revenue, 77.9% of YE25 accounts receivable, 63% of Q1'26 — combined UAE-affiliated share ~86% of FY25 (24+62; one disclosure, not four corroborating sources); the 424B4 counts G42 and MBZUAI as related parties of each other (ASC 850). 'Concentration did not go away; it rotated' (Patrick Moorhead, Moor Insights, via Stocktwits) is the honest gloss. Of the documents on file, only Cerebras's own filings disclose the purchases: MBZUAI's president signed the $350M purchase order (exhibit 10.17 to Cerebras's 2024 S-1), and MBZUAI's own pages (Jais, Jais 2) name Cerebras only as a model partner
    “For the year ended December 31, 2025, MBZUAI accounted for 62% of our total revenue.”
    Cerebras 424B4 · sec.gov
  • mbzuai-q3-202645%
    MBZUAI: 38% of Q3 2026 revenue (70% of Q3 2025) and 45% of the nine months to 9/30/26 (56% a year earlier), down from 62% of FY25 and 63% of Q1'26 as OpenAI rose to 34% of Q3 and 25% of the nine months; two customers made up 80% of accounts receivable at 9/30/26 (one, 78%, at YE25) — the filing does not name them. Combined with G42 (7% of Q3, 9% of the nine months) the UAE-affiliated share was 45% of Q3 and 54% of the nine months (our sum; ASC 850 related parties of each other): the rotation away from the UAE pair is real but still under way, and OpenAI is now the second concentration
    “accounted for 38% and 70% of our total revenue for the three months ended September 30, 2026 and 2025, respectively, and 45% and 56% for the nine months ended September 30, 2026 and 2025, respectively”
    Cerebras 10-Q Q3 2026 · sec.gov

Contested figures 2 not reconciled — every position side by side, with its source and tier

condor-galaxy-valueone entry, in its own words
'>$100M' for Condor Galaxy 1 (contemporaneous, phase ambiguity: initial 32 systems vs completed 64) vs '~$900M' for the nine-system network (announced 2023, never built past CG-1–3; the two figures were being conflated in press by late 2023). Neither has a first-party price, and neither reconciles to the $1.43B commitment — do not sum any of them 2023 press (SiliconANGLE/Register) vs DCD $900M piece (wayback)
post-ipo-positionone entry, in its own words
Semafor 12/2025: 'G42 taps out of Cerebras' (sell-down implied) — but no 13D/G, lock-up or prospectus line quantifies G42's post-IPO holding, while other holders did file 13Ds. The equity direction-of-travel is unsourced even though the revenue side is fully documented Semafor 12/22/2025 vs filing absence

More between Cerebras and G42

The record holds no other deal between them.

Everything between Cerebras and G42 →